Journal article

TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY

  • Kim, Y.H. Dermatology; Stanford University School of Medicine; Stanford United States
  • Ortiz-Romero, P.L. Dermatología; Institute i+12, Hospital Universitario 12 de Octubre, Universidad Complutense; Madrid Spain
  • Pro, B. Oncology; Northwestern University; Chicago United States
  • Sokol, L. Hematology/Oncology; H. Lee Moffitt Cancer Center; Tampa United States
  • Scarisbrick, J. Lymphoma Service; University Hospitals Birmingham; Birmingham United Kingdom
  • Musiek, A. Dermatology; Washington University; St. Louis United States
  • Vermeer, M. Dermatology; Leiden University Medical Center; Leiden Netherlands
  • Dummer, R. Dermatology; UniversitatsSpital Zurich; Zurich Switzerland
  • Halwani, A. Hematology; University of Utah; Salt Lake City United States
  • Fierro, M. Scienze Mediche; Università di Torino; Torino Italy
  • Moriya, J. Biostatistics; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
  • Leoni, M. Medical Sciences; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
  • Bagot, M. Service de Dermatologie; Hôpital Saint Louis, APHP, Inserm U976, Université Paris 7; Paris France
Show more…
  • 2019-6-12
Published in:
  • Hematological Oncology. - Wiley. - 2019, vol. 37, p. 285-286
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/121048
Statistics

Document views: 33 File downloads:
  • fulltext.pdf: 0